European Commission May Pursue More Antitrust Actions Against Pharma
This article was originally published in The Pink Sheet Daily
The EC is scrutinizing pharma practices that may delay generic entry and advocating changes in the patent system.
You may also be interested in...
The EMA has announced that it is ready to share information on generic marketing authorizations with other regulators, which should speed market access, but industry remains concerned about patent linkage and discriminatory regulatory standards.
The European Commission has published its annual report on the monitoring of patent settlements in Europe but has again failed to offer pharma firms the guidance and legal certainty they need.
The EU Parliament’s health committee has highlighted regulatory pitfalls within TTIP, while civil society elements decry its lack of transparency and potential impact on health care affordability.